April 2016 in “Journal of Investigative Dermatology” This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.
January 2008 in “Projeto: revista mensal de arquitetura” This article reviews the cutaneous reactions associated with targeted cancer therapies and highlights the importance of dermatologists recognizing these reactions to provide effective care but reports no clinical results.
April 2016 in “Journal of Investigative Dermatology” This study found that trametinib and vemurafenib increased sebum production and gene expression related to lipid accumulation in hamster sebocytes, which may help explain certain side effects in patients.
11 citations
,
June 2023 in “Journal of Cellular Biochemistry” This study suggests that BRAF inhibitors, particularly Encorafenib and Dabrafenib, may have potential applications in wound healing by targeting specific proteins involved in the healing process in murine models.